GEA Pharma Systems presented latest update of ConsiGmaTM Continuous Tableting Line (patents pending) to over 120 FDA participant

GEA Pharma Systems presented latest update of ConsiGmaTM Continuous Tableting Line (patents pending) to over 120 FDA participants  Send link  Print this page 
 
13 APR 2010
FDA - 1st CONTINUOUS MANUFACTURING SYMPOSIUM
(official name of the event)

GEA Pharma Systems presented latest update of ConsiGmaTM Continuous Tableting Line (patents pending) to over 120 FDA participants

The FDA recognises the value of continuous manufacturing and is working to raise the level of awareness of this technology amongst its review staff. As one initiative the 1st CONTINUOUS MANUFACTURING ONE DAY SYMPOSIUM was held, exclusively for FDA personnel, on March 11 2010 in Bethesda, MD.

There were a total of 124 people present: nearly all were from various FDA offices. Additionally 3 speakers from leading universities had been invited, 2 presentations came from Pfizer and GSK and as the only manufacturer of process equipment GEA Pharma Systems was invited to participate with a presentation.

The chairman's introductory presentation highlighted that in the view of the FDA that the use of continuous processing in pharmaceutical production will lead to an improvement in product quality. Additionally the chairman stressed that the FDA encourages pharmaceutical companies to go that way and that the agency is very supportive on this.

A further presentation on behalf of the FDA highlighted the benefits of continuous manufacturing such as: easy or no scale up, flexible batch size, fast development with less product, and constant quality and so enhanced patient safety. It also stressed the importance of plug flow in such processes.

During their joint presentation Kris Schoeters (Product Manager - Continuous Processes at GEA Pharma Systems) and Dr. Harald Stahl (Senior Pharmaceutical Technologist at GEA Pharma Systems) first introduced ConsiGmaTM Tableting Line as the solution developed by GEA Pharma Systems allowing continuous production from powder to tablets in only 20 minutes.

The presentation continued with the various control philosophies within the line - ranging from traditional fixed recipe control; via advanced process control with integrated feedback loops allowing to compensate for fluctuations of e.g. incoming materials; up to Real Time Release - as all Critical Quality Attributes (CQA) can be measured in-line (on a much higher frequency as it would be possible by any batch process). The presentation was completed by a discussion of data generated by Pharma companies during extended runs. Meanwhile more than 50 companies have tested over 80 different formulations in the competence centre in Belgium.

Two aspects of the ConsiGmaTM Continuous Processing approach were most well received. These were the assurance of plug flow over the entire process and the increased number of measurements of CQA which was confirmed by data from an uninterrupted 50h run resulting in 1.800.000 tablets. During the 50-hour test more than 960 in-line measurements were taken to determine critical quality attributes (CQA) such as Loss in Drying (LOD) or particle size distribution, while the content uniformity of the final tablets was assessed in-line more than 100 times.

Learn more about ConsiGmaTM Continuous Tableting Line at:
Interphex 2010 - April 20-22, 2010, New York - USA, booth number 1629.
TechnoPharm 2010 - April 27-29, 2010, Nuremberg - Germany, hall 1, stand 115.

GEA Pharma Systems is dedicated to innovation and thereby providing durable quality through its well-established brands: Aeromatic-FielderTM and ColletteTM - batch and continuous granulation, drying, pelletizing and coating; Buck® - contained materials handling; CourtoyTM - tablet compression; and LyophilTM - pharmaceutical freeze drying.

Suggested Articles

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.